Doxycycline in COVID-19: Learnings from the Asian Experience
Coronavirus disease 2019 (COVID19) : A World Health Organisation (WHO) declared global pandemic, has infected over millions of people by severe acute respiratory syndrome‐coronavirus‐2 (SARS-CoV-2), and billions have become victims of its direct and indirect socioeconomic squeal. While the efforts in the direction of vaccine development are yet to meet success, there are no well- established treatment options available. Early treatment, before the disease becomes severe, would be optimal. (1) Along with this objective, one of the emerging therapeutic candidates, Doxycycline, is a potent antimicrobial with both antiviral and anti-inflammatory activities. (2) The pandemic has manifested a diverse spectrum globally and it may be interesting to review the Asian experience with the use of Doxycycline in clinical practice settings for the management of COVID-19 infection.
Doxycycline added as Combination in Mild to Moderate COVID-19 Infections
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Doxycycline, click HERE